Latest news with #JeffreyBacha
Yahoo
15-07-2025
- Business
- Yahoo
Rakovina Therapeutics Granted DTC Eligibility to Expand U.S. Investor Access
VANCOUVER, British Columbia, July 15, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. ('Rakovina' or the 'Company') (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing next-generation cancer therapies through artificial intelligence (AI)-powered drug discovery, is pleased to announce that its shares are now eligible for electronic clearing and settlement through The Depository Trust Company (DTC). DTC eligibility streamlines the process for U.S. investors to trade Rakovina shares, enhancing liquidity and broadening market accessibility. DTC is a subsidiary of the Depository Trust & Clearing Corporation (DTCC), the largest securities depository in the world, providing settlement services to major U.S. stock exchanges. 'Achieving DTC eligibility is a meaningful step forward in increasing Rakovina's visibility and accessibility to a broader base of institutional and retail investors,' said Jeffrey Bacha, Executive Chairman of Rakovina Therapeutics. 'It removes a key barrier to efficient trading in the U.S., enhances liquidity, and establishes the foundation for deeper engagement with U.S. capital markets as we continue to execute our growth strategy.' Supporting Strategic Growth and Shareholder Value The designation eliminates previous barriers to entry for U.S. investors by enabling Rakovina shares to be traded electronically, reducing costs and processing times. This development supports the company's broader strategy to increase market participation and deliver long-term value to shareholders. The DTC announcement comes as Rakovina continues to advance its preclinical programs and explore strategic partnerships in AI-enhanced diagnostics and oncology therapeutics. Additional corporate developments are expected in the coming months as the company builds on its momentum and executes on its strategic roadmap. About Rakovina Therapeutics Therapeutics is a biopharmaceutical research company focused on the development of innovative cancer treatments. Our work is based on unique technologies for targeting the DNA-damage response powered by Artificial Intelligence (AI) using the proprietary Deep-Docking™ and Enki™ platforms. By using AI, we can review and optimize drug candidates at a much greater pace than ever before. The Company has established a pipeline of distinctive DNA-damage response inhibitors with the goal of advancing one or more drug candidates into human clinical trials in collaboration with pharmaceutical partners. Further information may be found at Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release. Notice Regarding Rakovina Therapeutics Forward-Looking Statements: This release includes forward-looking statements regarding the company and its respective business, which may include, but is not limited to, statements with respect to the proposed business plan of the company and other statements. Often, but not always, forward-looking statements can be identified by the use of words such as 'plans,' 'is expected,' 'expects,' 'scheduled,' 'intends,' 'contemplates,' 'anticipates,' 'believes,' 'proposes' or variations (including negative variations) of such words and phrases, or state that certain actions, events, or results 'may,' 'could,' 'would,' 'might,' or 'will' be taken, occur, or be achieved. Such statements are based on the current expectations of the management of the company. The forward-looking events and circumstances discussed in this release may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the company, including risks regarding the medical device industry, economic factors, regulatory factors, the equity markets generally, and risks associated with growth and competition. Although the company has attempted to identify important factors that could cause actual actions, events, or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events, or results to differ from those anticipated, estimated, or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made, and the company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. The reader is referred to the company's most recent filings on SEDAR+ for a more complete discussion of all applicable risk factors and their potential effects, copies of which may be accessed through the company's profile page at For Further Information Contact: Michelle Seltenrich, BSc MBA Director, Corporate Development IR@ 778-773-5432Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
11-07-2025
- Business
- Yahoo
Rakovina Therapeutics Congratulates Partner - Variational AI for Winning LifeSciencesBC's 2025 Emerging Biotech Company of the Year Award
Award Recognition underscores the importance of AI-driven drug discovery VANCOUVER, British Columbia, July 11, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. ('Rakovina' or the 'Company') (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing next-generation cancer therapies through AI-powered drug discovery proudly congratulates partner, Variational AI, on being honored as the 2025 Emerging Company of the Year – Biotech by Life Sciences BC. This prestigious award recognizes a British Columbia-based biotechnology company demonstrating exceptional progress and achievement of key strategic milestones, attributes that reflect Variational AI's impressive momentum and innovation in the field. Since entering into a partnership with Rakovina Therapeutics in September 2024, Variational AI has applied its Enki™ generative AI platform to accelerate the discovery of novel DNA damage response (DDR) kinase inhibitors. Most recently, the platform has been used to advance the KT-5000 series, the newest generation of synthetic small-molecule candidates targeting DDR pathways. This collaboration has produced multiple structurally novel compounds with favorable drug-like properties and activity in validated cancer cell lines. Early data suggest these candidates hold strong promise as brain-penetrant agents for difficult-to-treat tumors and represent a significant step forward in the Company's AI-powered discovery pipeline.'We're proud to see Variational AI recognized as Emerging Biotech Company of the Year,' said Jeffrey Bacha, Executive Chairman of Rakovina Therapeutics. 'This award highlights the transformative role of AI in drug discovery and reinforces the strength of our collaboration. Variational's Enki™ platform has helped us identify novel drug candidates with remarkable speed and precision, and we look forward to advancing these promising therapies together.'About Variational AI Variational AI has developed Enki™, the first commercially available foundation model for small-molecule drug discovery. By leveraging generative AI, Variational AI enables biopharmaceutical companies to rapidly discover and optimize novel, potent, safe, and synthesizable lead compounds at a fraction of the time and cost of traditional approaches. For more information, visit About Rakovina Therapeutics Therapeutics is a biopharmaceutical research company focused on the development of innovative cancer treatments. Our work is based on unique technologies for targeting the DNA-damage response powered by Artificial Intelligence (AI) using the proprietary Deep-Docking™ platform. By using AI, we can review and optimize drug candidates at a much greater pace than ever before. The Company has established a pipeline of distinctive DNA-damage response inhibitors with the goal of advancing one or more drug candidates into human clinical trials in collaboration with pharmaceutical partners. Further information may be found at Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release. Notice Regarding Rakovina Therapeutics Forward-Looking Statements: This release includes forward-looking statements regarding the company and its respective business, which may include, but is not limited to, statements with respect to the proposed business plan of the company and other statements. Often, but not always, forward-looking statements can be identified by the use of words such as 'plans,' 'is expected,' 'expects,' 'scheduled,' 'intends,' 'contemplates,' 'anticipates,' 'believes,' 'proposes' or variations (including negative variations) of such words and phrases, or state that certain actions, events, or results 'may,' 'could,' 'would,' 'might,' or 'will' be taken, occur, or be achieved. Such statements are based on the current expectations of the management of the company. The forward-looking events and circumstances discussed in this release may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the company, including risks regarding the medical device industry, economic factors, regulatory factors, the equity markets generally, and risks associated with growth and competition. Although the company has attempted to identify important factors that could cause actual actions, events, or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events, or results to differ from those anticipated, estimated, or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made, and the company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. The reader is referred to the company's most recent filings on SEDAR for a more complete discussion of all applicable risk factors and their potential effects, copies of which may be accessed through the company's profile page at For Further Information Contact:Michelle Seltenrich, BSc MBADirector, Corporate DevelopmentIR@
Yahoo
30-06-2025
- Business
- Yahoo
Rakovina Therapeutics Announces Results from 2025 Annual General Meeting
VANCOUVER, British Columbia, June 25, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0) ('Rakovina' or the 'Company'), a biopharmaceutical company advancing next-generation cancer therapies through artificial intelligence (AI)-powered drug discovery is pleased to announce the results of voting at its 2025 annual general meeting of shareholders held on June 25, 2025, in Vancouver, British Columbia (the 'Meeting'). All five members of the Company's board of directors named as nominees in its management information circular dated May 26, 2025 (the 'Circular') were elected as directors: Jeffrey Bacha, Dr. Dennis Brown, Alfredo De Lucrezia, Yevgeniy Meshcherekov and Dr. David Kideckel. In addition, at the Meeting, the shareholders of the Company: (i) approved the re-appointment of Davidson & Company LLP as the Company's auditor until the next annual general meeting of shareholders; (ii) approved the setting of the number of directors at five; and (iii) re-approved the Company's existing omnibus equity incentive plan as set out in the Circular. About Rakovina Therapeutics Inc. Rakovina Therapeutics is a biopharmaceutical research company focused on the development of innovative cancer treatments. Their work is based on unique technologies for targeting the DNA-damage response powered by Artificial Intelligence (AI) using proprietary, generative AI platforms. By using AI, they can review and optimize drug candidates at a much greater pace than ever before. The Company has established a pipeline of distinctive DNA-damage response inhibitors with the goal of advancing one or more drug candidates into human clinical trials in collaboration with pharmaceutical partners. Further information may be found at No regulatory authority has approved or disapproved the content of this press release. Neither the TSX Venture Exchange nor its Regulatory Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release. Notice Regarding Forward-Looking Statements This press release may contain 'forward-looking statements' regarding the Company and its respective business within the meaning of applicable Canadian securities laws, including, without limitations, statements regarding: the Company's objectives, goals, or future plans regarding its cancer treatments or proposed business plan and expected results of the Company's DDR platform. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by management, are inherently subject to significant business, economic, and competitive uncertainties and contingencies. Often, but not always, forward-looking statements can be identified by the use of words such as 'plans', 'is expected', 'expects', 'scheduled', 'intends', 'contemplates', 'anticipates', 'believes', 'proposes' or variations (including negative variations) of such words and phrases, or state that certain actions, events, or results 'may', 'could', 'would', 'might' or 'will' be taken, occur or be achieved. The forward-looking events and circumstances discussed in this press release may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including risks regarding the medical device industry, economic factors, regulatory factors, the equity markets generally, and risks associated with growth and competition. Although the Company has attempted to identify important factors that could cause actual actions, events, or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events, or results to differ from those anticipated, estimated, or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and the Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. The reader is referred to the Company's most recent filings on SEDAR+ for a more complete discussion of all applicable risk factors and their potential effects, copies of which may be accessed through the Company's profile page at For Further Information Contact: Michelle Seltenrich, BSc MBADirector, Corporate DevelopmentIR@
Yahoo
25-06-2025
- Business
- Yahoo
Rakovina Therapeutics Announces Results from 2025 Annual General Meeting
VANCOUVER, British Columbia, June 25, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0) ('Rakovina' or the 'Company'), a biopharmaceutical company advancing next-generation cancer therapies through artificial intelligence (AI)-powered drug discovery is pleased to announce the results of voting at its 2025 annual general meeting of shareholders held on June 25, 2025, in Vancouver, British Columbia (the 'Meeting'). All five members of the Company's board of directors named as nominees in its management information circular dated May 26, 2025 (the 'Circular') were elected as directors: Jeffrey Bacha, Dr. Dennis Brown, Alfredo De Lucrezia, Yevgeniy Meshcherekov and Dr. David Kideckel. In addition, at the Meeting, the shareholders of the Company: (i) approved the re-appointment of Davidson & Company LLP as the Company's auditor until the next annual general meeting of shareholders; (ii) approved the setting of the number of directors at five; and (iii) re-approved the Company's existing omnibus equity incentive plan as set out in the Circular. About Rakovina Therapeutics Inc. Rakovina Therapeutics is a biopharmaceutical research company focused on the development of innovative cancer treatments. Their work is based on unique technologies for targeting the DNA-damage response powered by Artificial Intelligence (AI) using proprietary, generative AI platforms. By using AI, they can review and optimize drug candidates at a much greater pace than ever before. The Company has established a pipeline of distinctive DNA-damage response inhibitors with the goal of advancing one or more drug candidates into human clinical trials in collaboration with pharmaceutical partners. Further information may be found at No regulatory authority has approved or disapproved the content of this press release. Neither the TSX Venture Exchange nor its Regulatory Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release. Notice Regarding Forward-Looking Statements This press release may contain 'forward-looking statements' regarding the Company and its respective business within the meaning of applicable Canadian securities laws, including, without limitations, statements regarding: the Company's objectives, goals, or future plans regarding its cancer treatments or proposed business plan and expected results of the Company's DDR platform. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by management, are inherently subject to significant business, economic, and competitive uncertainties and contingencies. Often, but not always, forward-looking statements can be identified by the use of words such as 'plans', 'is expected', 'expects', 'scheduled', 'intends', 'contemplates', 'anticipates', 'believes', 'proposes' or variations (including negative variations) of such words and phrases, or state that certain actions, events, or results 'may', 'could', 'would', 'might' or 'will' be taken, occur or be achieved. The forward-looking events and circumstances discussed in this press release may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including risks regarding the medical device industry, economic factors, regulatory factors, the equity markets generally, and risks associated with growth and competition. Although the Company has attempted to identify important factors that could cause actual actions, events, or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events, or results to differ from those anticipated, estimated, or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and the Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. The reader is referred to the Company's most recent filings on SEDAR+ for a more complete discussion of all applicable risk factors and their potential effects, copies of which may be accessed through the Company's profile page at For Further Information Contact: Michelle Seltenrich, BSc MBADirector, Corporate DevelopmentIR@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
05-05-2025
- Business
- Yahoo
Rakovina Therapeutics Showcases Preclinical Results of Novel AI-Discovered Cancer Therapies at AACR 2025
Data highlights novel PARP1 and ATR inhibitors with progress toward next-generation therapies for hard-to-treat malignancies VANCOUVER, British Columbia, April 29, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO), a biopharmaceutical company advancing next-generation cancer therapies through artificial intelligence (AI)-powered drug discovery, today announced the presentation of new preclinical data from two of its lead programs at the American Association for Cancer Research (AACR) Annual Meeting 2025. The first presentation highlighted Rakovina's PARP1-selective inhibitor program. Using the proprietary Deep Docking and generative platforms , Rakovina previously screened more than four billion potential drug-like molecules to identify a shortlist of top candidates. These compounds were synthesized and evaluated in Rakovina's laboratory facilities at the University of British presented at AACR demonstrated a new class of PARP1 inhibitors with significantly improved metabolic stability, including the lowest in vitro clearance rates and the longest half-life compared to other candidates currently in development. Early animal studies revealed strong plasma exposure and a promising pharmacokinetic profile suggestive of central nervous system (CNS) penetration — a potentially significant advantage in treating brain-involved malignancies. The second presentation showcased progress from Rakovina's ATR-specific inhibitor program, developed in partnership with Variational AI. Researchers identified a focused set of lead candidates predicted to be highly potent and selective against ATR, a key DNA damage response target. These candidates are also designed with the potential to cross the blood-brain barrier, an important feature for addressing cancers affecting the CNS. The top candidates are currently being synthesized for laboratory validation. 'Our ability to screen billions of molecules and advance top candidates to in vitro and in vivo validation within months — rather than years — exemplifies the transformative power of AI in drug discovery,' said Jeffrey Bacha, Executive Chairman of Rakovina Therapeutics. 'This acceleration gives us the opportunity to significantly reduce the time and cost required to bring new life-saving cancer treatments to patients.' The results presented at AACR reinforce the robustness of Rakovina's AI-enabled discovery platform. Moving forward, Rakovina will leverage these findings to further refine and train its AI models, with the goal of advancing best-in-class lead candidates for both the PARP1 and ATR programs into clinical development. The Company intends to collaborate with pharmaceutical partners to accelerate the path to the clinic and deliver novel therapies to patients in need. About Rakovina Therapeutics Inc. Rakovina Therapeutics is a biopharmaceutical research company focused on the development of innovative cancer treatments. Our work is based on unique technologies for targeting the DNA-damage response powered by Artificial Intelligence (AI) using the proprietary Deep-Docking™ and Enki™ platforms. By using AI, we can review and optimize drug candidates at a much greater pace than ever before. The Company has established a pipeline of distinctive DNA-damage response inhibitors with the goal of advancing one or more drug candidates into human clinical trials in collaboration with pharmaceutical partners. Further information may be found at Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release. Notice Regarding Rakovina Therapeutics Forward-Looking Statements: This release includes forward-looking statements regarding the company and its respective business, which may include, but is not limited to, statements with respect to the proposed business plan of the company and other statements. Often, but not always, forward-looking statements can be identified by the use of words such as 'plans,' 'is expected,' 'expects,' 'scheduled,' 'intends,' 'contemplates,' 'anticipates,' 'believes,' 'proposes' or variations (including negative variations) of such words and phrases, or state that certain actions, events, or results 'may,' 'could,' 'would,' 'might,' or 'will' be taken, occur, or be achieved. Such statements are based on the current expectations of the management of the company. The forward-looking events and circumstances discussed in this release may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the company, including risks regarding the medical device industry, economic factors, regulatory factors, the equity markets generally, and risks associated with growth and competition. Although the company has attempted to identify important factors that could cause actual actions, events, or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events, or results to differ from those anticipated, estimated, or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made, and the company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. The reader is referred to the company's most recent filings on SEDAR for a more complete discussion of all applicable risk factors and their potential effects, copies of which may be accessed through the company's profile page at For Further Information Contact:Michelle Seltenrich, BSc MBADirector, Corporate DevelopmentIR@
